Self-injectable extended release formulation of Remdesivir (SelfExRem): A potential formulation alternative for COVID-19 treatment

Manali Patki, Siddhant Palekar, Sandra Reznik, Ketan Patel

Research output: Contribution to journalArticlepeer-review

8 Scopus citations


There has been a growing and evolving research to find a treatment or a prevention against coronavirus 2019 (COVID-19). Though mass vaccination will certainly help in reducing number of COVID-19 patients, an effective therapeutic measure must be available too. Intravenous remdesivir (RDV) was the first drug receiving Food and Drug Administration (FDA) approval for the treatment of COVID-19. However, in a pandemic like COVID-19, it is essential that drug formulations are readily available, affordable and convenient to administer to every patient around the globe. In this study, we have developed a Self-injectable extended release subcutaneous injection of Remdesivir (SelfExRem) for the treatment of COVID-19. As opposed to intravenous injection, extended release subcutaneous injection has the benefits of reducing face-to-face contact, minimizing hospitalization, reducing dosing frequency and reducing overall health care cost. SelfExRem was developed using a biodegradable polymer, poly(lactic-co-glycolic acid) (PLGA), dissolved in a biocompatible vehicle. Six different batches were formulated using 2 different grades of low molecular weight PLGA and 3 different PLGA concentration. The force of injection of various polymeric solutions through 23–30-gauge needles were analyzed using a TA.XTplus texture analyzer. The time required for injection was evaluated both manually and by using an autoinjector. In vitro release of all the batches were carried out in 1% v/v tween 80 in phosphate buffer saline. The study indicated that SelfExRem developed with 15% w/v PLGA (75:25) provided a steady release of drug for 48 h and may be a breakthrough approach for the treatment of COVID-19.

Original languageEnglish (US)
Article number120329
JournalInternational Journal of Pharmaceutics
StatePublished - Mar 15 2021


  • Covid19
  • In situ depot formulations
  • Long-acting injectables
  • Remdesivir
  • SARS-CoV2

ASJC Scopus subject areas

  • Pharmaceutical Science


Dive into the research topics of 'Self-injectable extended release formulation of Remdesivir (SelfExRem): A potential formulation alternative for COVID-19 treatment'. Together they form a unique fingerprint.

Cite this